Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
about
Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemiaColony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemiaUse of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studyTo wake up cancer stem cells, or to let them sleep, that is the questionG-CSF and GM-CSF in NeutropeniaFourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignanciesUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesHaploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectivesCancer stem cells in basic science and in translational oncology: can we translate into clinical application?The recognition of N-glycans by the lectin ArtinM mediates cell death of a human myeloid leukemia cell lineCriteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies.Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia.Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.The hematopoietic stem cell niche.Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial.Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.WIPI-dependent autophagy during neutrophil differentiation of NB4 acute promyelocytic leukemia cells.Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs.PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells.Inhibition of GATE-16 attenuates ATRA-induced neutrophil differentiation of APL cells and interferes with autophagosome formation.Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patientsAcute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastomaProspective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML.Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantationAcquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.Granulocyte colony-stimulating factor and leukemogenesis.Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaThe colony-stimulating factors: use to prevent and treat neutropenia and its complications.Low DICER1 expression is associated with attenuated neutrophil differentiation and autophagy of NB4 APL cells.Animal models of acute myelogenous leukaemia - development, application and future perspectives.Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission.Autologous stem cell transplantation in the treatment of adults with acute myeloid leukaemia.Including historical data in the analysis of clinical trials: Is it worth the effort?Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma.
P2860
Q24202698-48F447D6-84D1-4A16-944E-51A40781F1E7Q24234458-830FF397-161B-4212-A6D3-64992B150BA6Q24670020-201CF601-1C54-48B6-96C5-339F79644C77Q26749632-210ED86D-673F-4E09-80C7-B00AF6983A81Q26800954-E1954193-E351-4828-BB89-234F39604AA1Q26830130-2CE6F50C-C157-4732-B8F1-D43936306616Q28071384-A366E97F-64D8-4375-96B6-101DB1103AB9Q28080452-BB617A15-7DFD-4CF2-8AF8-CD07AE0477CAQ28081844-E7BC0AC4-DAB6-4EB2-BF17-F44A711B3022Q28742329-F6213270-A706-4366-9B30-8F2E4E1B82D5Q33210668-96E7291E-D6B7-451B-925B-4556CB400618Q33364151-8A0BF83D-4F37-4EDD-81FE-3F4BFF6410E4Q33395035-10859393-DF25-4FD5-9C73-F2D582FA8E7FQ33396739-21B98752-C983-4379-B0A7-E8378863FCC3Q33607827-D703250B-BC49-4461-B9C2-654F1D18E92DQ33871452-43833724-5B62-4724-B503-71FC352DF9DEQ33949752-DFE713C0-BF72-42B6-BE53-5D77F91C3E1BQ34007677-96669392-8EC0-48F8-BC62-677A49A0A5CCQ34230583-7839F08E-0771-4740-AA1F-EB0AE4A85180Q34267963-1F9925AF-905A-4712-8807-BAA056AE14A0Q34478666-D7CF0702-B9F0-498C-8808-99230F2D38BFQ34597777-44201682-8A52-4060-A01B-249950EEDD6AQ34655572-E5B1A7ED-71A0-4FF5-AB20-C4FCA8C9B9FBQ34996869-58260220-4EEE-42D9-8D26-F545E4E2D6ABQ35529926-336B5057-3C9D-4578-8CC2-92FE2BC4713DQ35546219-8F9349E3-9B40-454C-BAFA-D443FA2E311AQ35643058-047E8804-2807-480B-BD59-2603DB2D13A8Q35794435-B97A80E4-709A-45C8-B6AE-196364F77B38Q35820983-5820AD86-8099-4CE7-B84D-48F36945FD36Q35847836-58F36352-9DC2-400D-98C9-7173A594A83EQ35859239-29A8A1E6-AFB6-4AEA-86D3-4517A900743EQ35953355-CFE14C19-B8A8-4DB3-806B-53D0E61B3A42Q35967278-8B136B70-7B5E-49AD-95FA-A7E97EEEDAADQ35970498-E3D23756-B1C4-41DB-8183-232C8562FFF1Q36066980-3AF3313D-05E1-4633-A3FA-FE4B182D67E5Q36196735-EC52B7A1-5F00-4D16-B27F-38BE13B4D9D2Q36255287-6AF6087A-A746-46F4-8BCB-10987C6286A5Q36315895-3D57C7C9-B306-4ADC-9DC7-F26165C6F8F0Q36322534-44CB54AD-89AA-433A-B38E-90703CA7D61DQ36393320-FF7DE3F5-B43F-413C-BD5C-3985DFD9D267
P2860
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Effect of priming with granulo ...... py for acute myeloid leukemia.
@ast
Effect of priming with granulo ...... py for acute myeloid leukemia.
@en
Effect of priming with granulo ...... py for acute myeloid leukemia.
@nl
type
label
Effect of priming with granulo ...... py for acute myeloid leukemia.
@ast
Effect of priming with granulo ...... py for acute myeloid leukemia.
@en
Effect of priming with granulo ...... py for acute myeloid leukemia.
@nl
prefLabel
Effect of priming with granulo ...... py for acute myeloid leukemia.
@ast
Effect of priming with granulo ...... py for acute myeloid leukemia.
@en
Effect of priming with granulo ...... py for acute myeloid leukemia.
@nl
P2093
P50
P356
P1476
Effect of priming with granulo ...... py for acute myeloid leukemia.
@en
P2093
Augustin Ferrant
Dutch-Belgian Hemato-Oncology Cooperative Group
Georgine de Greef
Harry Schouten
Leo Verdonck
Marc Boogaerts
Martin Fey
Matthias Theobald
Peter Huijgens
P304
P356
10.1056/NEJMOA025406
P407
P577
2003-08-01T00:00:00Z